← Back to Search

Topical Agent

TAT4 Gel concentration A for Nasolabial Folds

Phase 1
Waitlist Available
Research Sponsored by Topokine Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 21 days

Summary

This Phase 1, randomized, placebo-controlled, double-blind, healthy volunteer study tested the safety, tolerability, and plasma pharmacokinetics of two different concentrations of TAT4 Gel administered once daily to 50 cm2 of skin for 14 days.

Eligible Conditions
  • Lipoatrophy
  • Nasolabial Folds
  • Lipodystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 21 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Event rates

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: TAT4 Gel concentration BExperimental Treatment1 Intervention
TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
Group II: TAT4 Gel concentration AExperimental Treatment1 Intervention
TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
Group III: PlaceboPlacebo Group1 Intervention
Placebo product once daily to 50 cm2 for 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TAT4 Gel concentration A
2014
Completed Phase 1
~20
TAT4 Gel concentration B
2014
Completed Phase 1
~20

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Topokine Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
660 Total Patients Enrolled
1 Trials studying Nasolabial Folds
111 Patients Enrolled for Nasolabial Folds
~1 spots leftby Oct 2025